semaglutide prediabetes progression to diabetes step trial Effect of 2.4 mg once weekly on 10‐year type 2 risk in adults with overweight or obesity - Wilkinson - 2023 - Obesity Once-weekly semaglutide 7·2 mg in

We included adults with type 2 diabetes who initiated a GLP-1 RA (exenatide [introduced in Israel in 12.2007], liraglutide [2.2010], lixisenatide [1.2015], exenatide extended-release [11.2015], dulaglutide [4.2016], and semaglutide [8.2019]) or basal insulin between February 2010 to December 2019

The estimated hazard ratio (95% CI) was 0.80 (0.72, 0.90) (see Figure 2 and Table 6)

Adams B, Jacocks L, Guo H

Vandepol, S

GLP-1 and GLP-1 Receptor Agonists for the Treatment of Stroke Over the past several years, neuroprotective effects of GLP-1 and GLP-1 Ras have been shown in animal models of stroke, and advances in this area have now been updated

They shut down operations in what became one of the most significant enforcement actions against a grey-market peptide vendor in recent memory